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Abstract
X-linked lymphoproliferative disease (XLP) is a primary immunodeficiency caused by mutations in SH2D1A which encodes
SAP. SAP functions in signalling pathways elicited by the SLAM family of leukocyte receptors. A defining feature of XLP is
exquisite sensitivity to infection with EBV, a B-lymphotropic virus, but not other viruses. Although previous studies have
identified defects in lymphocytes from XLP patients, the unique role of SAP in controlling EBV infection remains unresolved.
We describe a novel approach to this question using female XLP carriers who, due to random X-inactivation, contain both
SAP
+ and SAP
2 cells. This represents the human equivalent of a mixed bone marrow chimera in mice. While memory CD8
+ T
cells specific for CMV and influenza were distributed across SAP
+ and SAP
2 populations, EBV-specific cells were exclusively
SAP
+. The preferential recruitment of SAP
+ cells by EBV reflected the tropism of EBV for B cells, and the requirement for SAP
expression in CD8
+ T cells for them to respond to Ag-presentation by B cells, but not other cell types. The inability of SAP
2
clones to respond to Ag-presenting B cells was overcome by blocking the SLAM receptors NTB-A and 2B4, while ectopic
expression of NTB-A on fibroblasts inhibited cytotoxicity of SAP
2 CD8
+ T cells, thereby demonstrating that SLAM receptors
acquire inhibitory function in the absence of SAP. The innovative XLP carrier model allowed us to unravel the mechanisms
underlying the unique susceptibility of XLP patients to EBV infection in the absence of a relevant animal model. We found
that this reflected the nature of the Ag-presenting cell, rather than EBV itself. Our data also identified a pathological
signalling pathway that could be targeted to treat patients with severe EBV infection. This system may allow the study of
other human diseases where heterozygous gene expression from random X-chromosome inactivation can be exploited.
Citation: Palendira U, Low C, Chan A, Hislop AD, Ho E, et al. (2011) Molecular Pathogenesis of EBV Susceptibility in XLP as Revealed by Analysis of Female Carriers
with Heterozygous Expression of SAP. PLoS Biol 9(11): e1001187. doi:10.1371/journal.pbio.1001187
Academic Editor: Bill Sugden, University of Wisconsin-Madison, United States of America
Received February 17, 2011; Accepted September 16, 2011; Published November 1, 2011
Copyright:  2011 Palendira et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The Tangye lab is supported by grants and fellowships awarded by the XLP Research Trust (UK) (www.xlpresearchtrust.org), Cancer Council New South
Wales (Australia) [www.cancercouncil.com.au], the Association for International Cancer Research (UK) [www.aicr.org.uk], and the National Health and Medical
Research Council of Australia [www.nhmrc.gov.au]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
Abbreviations: APC, Ag presenting cell; B-LCL, B-lymphoblastoid cell lines; CMV, cytomegalovirus; CRACC, CD2-like receptor-activating cytotoxic cell; EBV,
Epstein Barr virus; Flu, influenza; SAP, SLAM-associated protein; SLAM, signalling lymphocytic activation molecule; TEMRA, effector memory cells expressing
CD45RA; XLP, X-linked lymphoproliferative disease
* E-mail: s.tangye@garvan.org.au
Introduction
X-linked lymphoproliferative disease (XLP) is an inherited
primary immunodeficiency caused by mutations in SH2D1A,
which encodes the cytoplasmic adaptor protein SLAM-associated
protein (SAP) [1–3]. SAP functions as an adaptor protein by
associating with members of the SLAM family of surface
receptors—SLAM (CD150), 2B4, NTBA, CD84, CD229, and
possibly CRACC [4–7]—that are expressed on a variety of
hemopoietic cells. A defining characteristic of XLP is extreme
sensitivity to infection with EBV (reviewed in [7–9]). Thus, in
contrast to infection of healthy individuals, which is self-limiting,
exposure of XLP patients to EBV induces a vigorous and
uncontrolled immune response involving polyclonally activated
PLoS Biology | www.plosbiology.org 1 November 2011 | Volume 9 | Issue 11 | e1001187leukocytes. Despite such immune activation, XLP patients fail to
control EBV infection, which results in severe and often-fatal
fulminant infectious mononucleosis [7–9]. XLP patients who
survive primary EBV infection can develop hypogammaglobulin-
emia and B-cell lymphoma, although exposure to EBV is not a
prerequisite for these clinical manifestations [8,9]. Strikingly, XLP
patients do not display the same degree of vulnerability towards
other herpes viruses—herpes simplex virus, cytomegalovirus
(CMV), varicella zoster—which can cause life-threatening infec-
tions in individuals with other immunodeficiencies [10]. This
highlights the unique role of EBV in the pathogenesis of XLP,
and the critical—albeit undefined—role of SAP in anti-EBV
immunity.
XLP is associated with a diverse range of lymphocyte defects
including abolished NKT cell development [11,12], compromised
humoral immunity [13–15], and impaired functions of CD4
+ T
cells [13,16–18], CD8
+ T cells [19,20], and NK cells [21–27]. This
reflects the involvement of SAP in multiple signalling pathways.
Given the complexity of the immunological abnormalities in XLP
patients, it is unclear which of them underlies their unique
susceptibility to EBV. While the defective response of NK cells
following engagement of 2B4 or NTB-A may contribute to the
susceptibility to EBV in XLP [22,24,26,27], it is unlikely to be the
predominant cause since a deficiency in either the absolute
number of NK cells or NK cell cytotoxicity in the presence of
intact T cell development and function in humans is associated
with more generalised susceptibility to multiple viruses (reviewed
in [28]). Similarly, while NKT cells may have a role in anti-viral
immunity, the impact of an NKT cell deficiency on EBV
sensitivity in XLP is unclear because patients with other
immunodeficiencies have also been reported to lack NKT cells,
yet they do not develop fulminant infectious mononucleosis
[29–31]. Lastly, while several previous studies have investigated
the function of CD8
+ T cells in XLP [19,20,32], it is difficult to
separate direct effects of SAP deficiency in these cells from indirect
effects that may result from lack of ‘‘help’’ from either functionally
impaired SAP-deficient CD4
+ T cells or NK cells, or the absence
of NKT cells, all of which can promote CD8
+ T cell responses
[33–36]. Furthermore, these studies of SAP-deficient CD8
+ T cells
have not provided an explanation as to why XLP patients are so
vulnerable to infection with EBV, but not with other pathogens.
In addition to these issues, delineating the EBV-specific defect in
XLP has been hindered by the lack of an appropriate
experimental model. Thus, while SAP-deficient mice have proved
key to elucidating mechanisms underlying some of the immuno-
logical defects in XLP [4,7,9], they cannot directly address the
question of EBV susceptibility because neither EBV nor its close
relatives in other primates infect mice, and no mouse virus can
reproduce EBV’s biology or its strictly B-lymphotropic means of
persistence [37]. The question of EBV pathogenesis therefore can
only be answered using a human model in which SAP-deficient
immune cells develop in an otherwise intact immune system.
Fortuitously, female carriers of XLP are healthy [38] and harbour
both SAP-positive and SAP-negative T cells through random
inactivation of the X-chromosome [11].
Here we demonstrate that such XLP carriers provide an ideal
model for elucidating the role of SAP in anti-viral immune
responses in humans. XLP carriers were shown to contain both
SAP
+ and SAP
2 T cells, which allowed us to determined which
virus-specific responses were dependent on SAP. While both SAP
+
and SAP
2 CMV or influenza-specific memory CD8
+ T cells were
able to respond to their cognate peptides, EBV-specific memory
CD8
+ T cells were exclusively restricted to the SAP
+ population,
revealing a specific requirement for SAP in anti-EBV immunity.
Further analysis of the response of SAP
2 CD8
+ T cells to different
Ag-presenting cells (APC) showed that SAP is required for B cell-
mediated CD8
+ T cell responses but not for responses induced by
other APCs. Our studies further demonstrated that an important
function of SAP was to prevent the delivery of inhibitory signals
downstream of SLAM family receptors on CD8
+ T cells following
interaction with their ligands on target B-cells. These data provide
compelling evidence that the unique susceptibility to EBV
infection in XLP patients is due to the inability of SAP
2 CD8
+
T cells to respond to Ag-presenting B cells due to inhibitory
signalling mediated by SLAM family receptors, rather than an
inability to recognise and respond to EBV Ags.
Results
Lymphocyte Defects Characteristic of XLP Patients Are
Not Present in XLP Carriers
We analysed seven female carriers of XLP, each of whom was
confirmed as heterozygous at the SH2D1A locus by sequencing
genomic DNA (Figure 1A,B). Analysis of lymphocyte subsets
revealed that these carriers, unlike XLP patients [11,15,16], had
normal frequencies of total and isotype switched memory B cells
(Figure 1C,D,F) and NKT cells (Figure 1E,G). The proportions of
memory CD8
+ and CD4
+ T cells were also within the range of
healthy controls (unpublished data). This is consistent with XLP
carriers being asymptomatic and lacking evidence of any obvious
deficiency in anti-viral immune responses, including against EBV
[38,39].
XLP Carriers Have Both SAP
+ and SAP
2 CD8
+ T Cells
Intracellular flow cytometric analysis using a SAP-specific
monoclonal antibody (mAb) enabled us to identify SAP
expression in different cell populations. SAP was expressed in
Author Summary
X-linked lymphoproliferative disease (XLP) is an immuno-
deficiency caused by mutations in the SH2D1A gene,
which encodes a cytoplasmic component, SAP involved in
a signalling pathway in certain populations of immune
cells. The Achilles’ heel in XLP is extreme sensitivity to
Epstein-Barr virus (EBV) infection. Although EBV infection
in normal individuals is generally innocuous, in XLP it can
be fatal. Strikingly, individuals with XLP do not display this
same vulnerability to other viruses, and here we investi-
gate what immune defects underlie this specific suscep-
tibility. We developed a system to examine the behaviour
of immune cells that are identical with the exception of
whether or not they have a functional SH2D1A gene. This
approach uses human female carriers of XLP (one of their X
chromosomes carries the mutation). Following the process
of X-chromosome inactivation in female cells, which is
random, individuals harbour T cells that express the
normal SH2D1A gene as well as cells that express the
mutated version. We found that SAP-deficient CD8
+ T cells
fail to be activated by antigen-presenting B cells, but are
activated by other antigen-presenting cell types. Since EBV
selectively infects B cells, the exquisite sensitivity in XLP to
EBV infection results from the ability of the virus to
sequester itself in B cells, which can only induce a cytotoxic
T cell response in SAP-sufficient cells. Thus, the functional
defect in SAP-deficient CD8
+ T cells does not relate to a
specific virus but rather to the nature of the target cell
presenting viral epitopes.
Mechanism of Susceptibility to EBV in XLP
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+ T cells, CD8
+ T cells, and NK cells from normal donors
(Figure 2A), but not in the same lymphocyte populations obtained
from XLP patients (Figure 2B). Using this approach we
confirmed heterozygous SAP expression (i.e., 40%–60% of the
cells being SAP
+/2) within the T and NK cell compartments of
XLP carriers (Figure 2C,D). There was no significant difference
Figure 1. Immune features of heterozygote carriers of XLP. (A) Forward (upper) and reverse (lower) genomic DNA sequences of affected
exons in three representative female XLP carriers. (B) The wild-type and mutated alleles and resulting amino acid changes in the seven XLP carriers
used in this study. (C–E) PBMCs from XLP carriers were labelled with mAb against CD20, CD27, and IgG/A/E or CD3, TCRVb11, and TCR Va24. The
frequency of: (C, F) B cells expressing CD27 (i.e., memory cells); (D) memory B cells expressing isotype switched Ig; and (E, G) NKT cells were then
determined. The values depicted in dot plots in (C), (D), and (E) correspond to the mean frequency of total memory B cells, isotype switched memory
B cells, and NKT cells, respectively. Reference values for healthy controls have been previously published [15,16,29].
doi:10.1371/journal.pbio.1001187.g001
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PLoS Biology | www.plosbiology.org 3 November 2011 | Volume 9 | Issue 11 | e1001187in the frequency of CD8
+ central memory (CD45RA
2CCR7
+)T
cells (Figure 2C) or NK cells (Figure 2D) that were SAP
2 or
SAP
+. However, significantly more naı ¨ve CD8
+ T cells were
SAP
2 (p=0.045), whereas more effector memory (CD45RA
2
CCR7
2)a n dT EMRA (effector memory cells expressing CD45RA)
cells were SAP
+ (Figure 2C). The greater frequency of SAP
2 cells
in the naı ¨ve compartment would be consistent with proposed
functions for SAP in negatively regulating T cell responses in
mice in vivo [40,41] and in promoting apoptosis of human cells
in vitro [42,43]. In contrast to T and NK cells, .90% of NKT
cells in XLP carriers were SAP
+ (Figure 2E), consistent with the
absolute requirement of SAP for their development [11,12]. SAP
was not detected in human B cells (Figure 2A,F) [15], supporting
the concept that intrinsic defects in T cells, NK cells, and
NKT cells, rather than B cells, are responsible for the XLP
phenotype.
Figure 2. Heterozygous SAP expression in T cells and NK cells from XLP carriers. (A, B) PBMCs from a healthy donor (A) or an XLP patient
(B) were incubated with mAb against CD3, CD4, CD8, CD56, and CD20. The cells were then fixed and permeabilised and labelled with an isotype
control (grey histogram) or anti-SAP (red histogram) mAb. Expression of SAP in CD3
+ T cells, CD8
+ and CD4
+ T cells, B cells (CD20
+), and NK
(CD3
2CD56
+) cells was then determined. (C–F) PBMCs from XLP carriers were labelled with mAb specific for CD3, CD8, CD45RA, CCR7, CD56,
TCRVb11, TCRVa24, or CD20. The cells were then fixed and permeabilised and incubated with isotype control (blue histogram) or anti-SAP mAb (red
histogram). SAP expression and the frequency of SAP
2 and SAP
+ cells was determined for: (C) total CD8
+ T cells, and subsets of naı ¨ve
(CD45RA
+CCR7
+), central memory (CD45RA
2CCR7
+), effector memory (CD45RA
2CCR7
2), or TEMRA (CD45RA
+CCR7
2) cells; (D) NK cells (CD3
2CD56
+);
(E) NKT cells (CD3
+TCRVb11
+TCRVa24
+); and (F) B cells (CD20
+).
doi:10.1371/journal.pbio.1001187.g002
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+ While CMV and Flu-
Specific Cells Are SAP
+ or SAP
2
To determine the contribution of SAP
+ and SAP
2 CD8
+ T cells
to antiviral immunity, we analysed SAP expression in populations
of memory CD8
+ T cells that were specific for EBV, CMV, and
influenza (Flu), as detected by soluble peptide:MHC class I
complexes (i.e., tetramers). Five of the XLP carriers had MHC
class I types that allowed epitope-specific cells to be visualised by
this approach. The frequency of CMV and Flu-specific CD8
+ T
cells within the SAP
+ population (CMV: range 21%–72%; mean
6 sem: 46.3%612.3%, n=4; Flu: 8% and 46%; mean:
27.0%619%) was not significantly different from that within the
SAP
2 population (CMV: 55.7%612.3%, n=4 [p=0.78]; Flu:
73.0%619%, n=2) (Figure 3A,B). In stark contrast, almost all
EBV-specific CD8
+ T cells expressed SAP (95.0%62.9% versus
5.0%62.9% in SAP
2 cells, n=4; p=0.004; Figure 3A,B). The
same clear-cut distinction was seen when the functional response
of virus-specific CD8
+ T cells to various antigenic peptide
challenges was assessed in vitro. Following stimulation of PBMCs
from XLP carriers with CMV or Flu Ags, both SAP
+ and SAP
2
cells produced IFN-c (Figure 3C,E) and expressed surface CD107a
(Figure 3D,E), an indicator of the ability of cells to degranulate
[44,45]. However, when PBMCs were stimulated with various
EBV peptides, including those from both lytic and latent Ags, only
SAP
+ CD8
+ T cells responded (Figure 3C–E). Consistent with the
recognition of EBV tetramers, the differences in the responses of
SAP
+ and SAP
2 CD8
+ T cells to in vitro stimulation with EBV
peptides were highly significant (p=0.0001; Figure 3E). Taken
together these data demonstrated that the CD8
+ T cell response to
EBV infection in healthy XLP carriers had been preferentially
recruited from SAP
+ T cells, whereas the CD8
+ T cell response to
other viruses showed no preference for SAP-expressing cells.
Phenotypic Features of SAP
2 and SAP
+ Cells
One explanation for the disparate responses of SAP
2 and SAP
+
CD8
+ T cells to EBV, but not to other viruses, may result from
differential expression of co-stimulatory or inhibitory molecules in
the absence of SAP. Thus, we determined the phenotype of SAP
2
and SAP
+ cells with respect to expression of a suite of molecules
known to regulate CD8
+ T cell function. Expression of the co-
stimulatory/activation/effector molecules CD27, CD28, CD38,
OX40, ICOS, perforin, and granzyme B did not differ between
SAP
2 and SAP
+ CD8
+ T cells, irrespective of whether thecells were
of a naı ¨ve or memory phenotype. Similarly molecules known to
inhibit lymphocyte function—PD-1, BTLA—were comparably
expressed on SAP
2 and SAP
+ naı ¨ve and memory CD8
+ T cells
(unpublished data). We also analysed the TCR repertoire of SAP
2
and SAP
+ cells by determining expression of distinct TCR Vb
chains by flow cytometry to deduce whether the TCR usage was
significantly different between these cells. Although this approach
may not be sufficiently sensitive to detect restricted diversity, the
TCR repertories of SAP
2 and SAP
+ cells appeared to be generally
similar (Table 1). The few biased TCR Vb chains used in two
carriers (#1, #3; Table 1) probably reflects the responses of
different subsets of effector/memory cells to different viruses and
their unique antigenic epitopes. Thus, lack of SAP expression does
not appear to alter thymic selection of CD8
+ T cells, or their ability
to acquireexpression ofreceptors involved inregulatinglymphocyte
function. Consequently, it is unlikely that perturbed selection or
activation of SAP
2 CD8
+ T cells through co-stimulatory and
regulatory receptors underlies their poor responsiveness to
stimulation with EBV. Rather, this is likely a direct effect of SAP
deficiency.
SAP Is Required for CD8
+ T Cell-Mediated Cytotoxicity of
Ag-Presenting B Cells
The selective dependence of EBV-specific CD8
+ T-cell-
mediated immunity on SAP raised the question of which T-cell
extrinsic mechanisms might explain the differences between the
responses to EBV versus CMV and Flu. Since Ag presentation was
a logical place to start, we developed an approach that would allow
us to analyse the ability of SAP
2 T cells to respond to distinct types
of APCs. Thus, multiple SAP
2 and SAP
+ clonal pairs were
established from different XLP carriers (Figure S1) and then tested
for their ability to recognise cognate peptides presented on
different APC targets, namely autologous EBV-transformed
lymphoblastoid cell lines (B-LCLs), or HLA class I-matched
monocytes or fibroblasts. SAP
+ CD8
+ T cell clones responded to
their specific peptide regardless of the nature of the APC, as
evidenced by enhanced IFN- c production (Figure 4A, upper
panels), acquisition of expression of CD107a (Figure 4B–E, Figure
S2A upper panel) and lysis of Ag-presenting target cells
(Figure 4F,G). In contrast, SAP
2 CD8
+ T cell clones responded
poorly upon stimulation with peptide-pulsed B-LCLs compared to
SAP
+ clones, irrespective of whether the clones were specific for
CMV (Figure 4A,B, Figure S2A lower panels) or Flu (Figure 4C
lower panel, Figure 4D,F). Importantly the defective responses of
SAP
2 clones to specific Ag presented on B-LCLs did not reflect a
generalised activation defect because these cells responded as well
as SAP
+ cells following PMA/ionomycin stimulation (Figure 4A–
C, Figure S2A). Strikingly, the impairment was restricted to Ag
presented in a B cell context. Thus, the same SAP
2 CMV-specific
or Flu-specific clones responded as well as their SAP
+ counterparts
to peptides presented on HLA-matched monocytes (Figure 4B,
Figure S2), or fibroblasts (Figure 4C,E,G).
We extended these studies by assessing induction of CD107a
expression by SAP
2 and SAP
+ CD8
+ T cells within a CMV-
specific T cell line in response to presentation of specific Ag by in
vitro–derived dendritic cells (DCs) compared to B-LCLs. Although
the frequency of total CD8
+ T cells responding to CMV peptides
was similar irrespective of whether B-LCLs or DCs were the APC
(,5%–6%), the SAP
+ CD8
+ T cells predominated the response
when CMV-derived peptides were presented by B-LCLs (.90%
of responding cells; Figure S2B). In contrast, both SAP
2 and SAP
+
CD8
+ T cells responded to Ag-presenting DCs (35% and 65% of
responding cells, respectively; Figure S2B). These findings are
entirely consistent with the data for Ag-specific paired SAP
2 and
SAP
+ clones (Figure 4, Figure S2A), and together provide
compelling evidence for an important role for SAP in mediating
CD8
+ T cell recognition of B cell targets.
It would be ideal to also demonstrate that EBV-specific SAP-
deficient CD8
+ T cells are unable to respond to Ag endogenously
presented by B cells. This could not be investigated using XLP
carriers due to the extreme paucity of EBV-specific cells within the
SAP
2 subset of CD8
+ T cells in these individuals (see Figure 3). To
address this, we generated EBV-specific CD8
+ T cell lines from an
XLP patient with a well-characterised loss-of-expression mutation
in SH2D1A ([F87S], XLP#3 in [46]). This was achieved by
repeatedly expanding their purified CD8
+ T cells on autologous
EBV-transformed B-LCLs, as performed previously for other
SAP-deficient patients [19]. As expected, EBV-specific CD8
+ T
cells from normal donors efficiently lysed autologous B-LCL target
cells. In contrast, there was a profound defect in the ability of XLP
Mechanism of Susceptibility to EBV in XLP
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+ cells into the EBV-specific memory CD8
+ T cell compartment. (A, B) XLP carrier PBMC were
labelled with specific MHC class I/peptide complexes together with anti-CD8 mAb; the cells were then fixed/permeabilised and incubated with anti-
SAP mAb. The proportion of SAP
+ and SAP
2 cells that were specific for the different viruses was then determined. Dot plots in (A) depict SAP
expression in tetramer
+ cells from a carrier with detectable populations of CMV-, Flu-, and EBV-specific CD8
+ T cells. The graphs in (B) depict
proportions of SAP
+ and SAP
2 cells amongst EBV, CMV, or Flu-specific CD8
+ T cells from five different XLP carriers. (C–E) PBMCs from XLP carriers were
either unstimulated or stimulated with EBV, CMV, or Flu peptides, or with PMA/ionomycin. Expression of (C) IFN-c or (D) CD107a by SAP
2 and SAP
+
Mechanism of Susceptibility to EBV in XLP
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+ T cells to lyse autologous B-LCLs (Figure S2C, panel [i]).
For these experiments, the donor and XLP patient were HLA
matched. This allowed assessment of the ability of EBV-specific
CD8
+ T cells to lyse B-LCL derived from a SAP-sufficient donor
or SAP-deficient XLP patient, and thereby to determine whether
the cytotoxic defect of XLP CD8
+ T cells resulted from impaired
presentation of EBV Ag by SAP-deficient B-LCL. When this
experiment was performed, XLP CD8
+ T cells proved to be
equally defective in killing allogeneic B-LCLs, which contrasted
the behaviour of EBV-specific CD8
+ T cell lines from normal
donors (Figure S2C panel [ii]). Importantly, the inability of XLP
CD8
+ T cells to lyse B-LCL target cells did not appear to result
from altered expression of lytic effector molecules since acquisition
of perforin and granzyme B by XLP CD8
+ T cells was comparable
to that of normal CD8
+ T cells (Figure S2C panel [iii]). This is
consistent with the reduced cytotoxicity of SAP-deficient cells
resulting from impaired recognition of B-LCL targets, which
subsequently compromises immune synapse formation between
effector and target cells, and polarisation of lytic mediators
[19,47].
SAP
+ and SAP
2 T Cells Display Comparable Expression of
the SLAM Family of Receptors, Yet Their Ligands Are
Differentially Expressed by Distinct Types of APCs
To begin to elucidate the mechanism underlying compromised
SAP
2 CD8
+ T cell recognition of peptide-pulsed B cell targets and
explore ways in which function might be restored, we examined
the expression of SAP-associating receptors on subsets of SAP
2
and SAP
+ T cells. SAP associates with the cytoplasmic domains of
SLAM, 2B4, CD84, NTB-A, CD229, and possibly CRACC [4,7].
When expression of these molecules was assessed on lymphocytes
from XLP carriers, we found no significant differences in their
expression on SAP
2 and SAP
+ CD8
+ T cells within the naı ¨ve and
TEMRA subsets (p.0.05; Figure 5A; Figure S3). Most of these
molecules were also expressed comparably on SAP
2 and SAP
+
central memory and effector memory CD8
+ T cells. However,
there were significant differences in the expression levels of 2B4
and NTB-A on SAP
2 and SAP
+ central memory CD8
+ T cells,
and of 2B4 and CRACC on SAP
2 and SAP
+ effector memory
CD8
+ T cells, with them being lower on SAP
2, relative to SAP
+,
cells. While these differences were statistically significant, the net
differences in expression were ,2-fold. Thus, it is unknown
whether this would translate to a biological effect; furthermore, it is
important to highlight that CRACC has been reported to function
independently of SAP, at least in the context of human NK cells
[48]. Thus, the lower level of CRACC on SAP
2 cells will be
inconsequential at least with respect to SLAM-receptor/SAP-
dependent signalling and lymphocyte activation. These data
generally imply that, at the cell surface, SAP
2 and SAP
+ CD8
+
T cells are similarly capable of interacting with relevant ligands of
the SLAM family.
The next step was to examine expression of ligands of the
SLAM family receptors on different APCs because expression of
these molecules on APCs could also influence the outcome of
CD8
+ T cell-mediated recognition of target cells. While 2B4
interacts with CD48, the other SLAM family receptors are self-
ligands [4,7]. In contrast to SAP
+ and SAP
2 CD8
+ T cells, there
were substantial differences in expression of SLAM family ligands
by B-cell and non-B-cell APCs. NTB-A expression was highest on
B cells and B-LCLs, while CD48 was highest on monocytes and B-
LCLs (Figure 6A,B). B-LCLs also expressed higher levels of
CD229, CRACC, and SLAM than resting B cells and monocytes
(Figure 6A,B). Interestingly, NTB-A, CD48, and CD229 were all
absent from in vitro–derived DCs; however, DCs did express
CRACC, SLAM, and CD84 (Figure 6A,B). The relative levels of
these molecules on DCs were similar to monocytes, with CRACC
and SLAM being less, and CD84 being greater, than on B-LCLs
(Figure 6A,B). Unlike APCs of hematopoietic origin, fibroblasts
did not express any SLAM family ligands (Figure 6A,B). Thus,
APCs exhibit substantial differences in their pattern of expression
of SLAM family ligands.
NTB-A and 2B4 Regulate CD8
+ T Cells by Inhibiting Their
Effector Function in the Absence of SAP
The above findings implied that engagement of distinct arrays
of co-stimulatory receptors on SAP
2 and SAP
+ CD8
+ T cells by
Table 1. TCR Vb expression by SAP
2 and SAP
+ CD8
+ T cells in
XLP carriers.
TCR Vb Chain % CD8
+ T Cells Expressing TCR Vb Chains
XLP Carrier 1 XLP Carrier 3 XLP Carrier 4
SAP
2 SAP
+ SAP
2 SAP
+ SAP
2 SAP
+
1 4.0 1.45 3.35 3.68 4.77 5.45
2 3.32 0.85 2.33 3.71 8.3 5.97
3 0.62 0.47 0.55 0.39 0.85 1.28
4 1.61 0.27 1.53 1.71 3.35 1.8
5.1 1.9 5.95 2.6 17.1 4.2 2.9
5.2 1.16 0.49 1.1 0.52 1.68 2.8
5.3 1.02 0.27 4.4 1.93 4.64 6.37
7.1 12.6 0.42 1.8 3.08 5.37 3.85
7.2 1.25 2.62 1.62 3.2 1.98 3.96
8 3.06 7.18 1.35 4.14 4.1 7.22
9 0.54 0.22 0.22 1.61 0.71 1.54
11 4.80 34.10 19.8 6.3 4.93 4.74
12 1.53 0.5 1.04 0.8 0.98 0.9
13.1 4.4 9.81 4.7 2.5 4.37 4.27
13.2 1.46 0.5 1.37 2.1 1.48 1.31
13.6 0.88 0.27 2.9 0.12 1.2 1.14
14 0.7 0.37 9.85 1.0 0.84 0.4
16 1.50 0.59 0.86 1.06 2.3 2.44
17 3.67 3.35 3.9 2.25 7.36 5.78
18 0.79 0.35 0.94 1.5 1.1 0.94
20 0.39 0.34 0.34 0.61 1.7 0.9
21.3 1.03 0.52 1.21 4.5 0.8 1.0
22 2.90 0.9 2.3 1.14 4.2 3.0
23 1.81 0.35 3.35 1.65 3.7 2.58
doi:10.1371/journal.pbio.1001187.t001
CD8
+ T cells was determined after 4–6 h. The values represent the proportion of responding cells that were SAP
2 or SAP
+. (E) Summary of data
obtained from analysis of CD8
+ T cells from different carriers to determine secretion of IFN-c or degranulation (i.e., CD107a expression) by SAP
+ and
SAP
2 cells in response to EBV, CMV, and Flu peptides. ‘‘n’’ represents the number of carriers studied for each viral response.
doi:10.1371/journal.pbio.1001187.g003
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PLoS Biology | www.plosbiology.org 8 November 2011 | Volume 9 | Issue 11 | e1001187ligands expressed on different APCs would modulate the
acquisition of effector function of the responding CD8
+ T cells.
This would be consistent with the ability of SLAM family receptors
to switch their function from activating or inhibitory depending on
the presence of SAP [22,24,32]. We therefore explored the
possibility that defined interactions between specific SLAM
receptors on SAP
+ or SAP
2 CD8
+ T cells and their ligands on
APCs differentially regulated cytotoxicity.
We first examined the ability of SAP
+ and SAP
2 CD8
+ T cells
to respond to the Hodgkin’s lymphoma cell line HDLM2. This
line was chosen as a target cell because (a) it lacked expression of
all SLAM family ligands with the exception of SLAM/CD150
itself (Figure 7A), (b) SLAM has been reported to enhance the
cytotoxicity of human CD8
+ T cells [49], and (c) SLAM was
expressed at the highest levels on B cells relative to other APCs
(Figure 6), revealing it as a candidate molecule to regulate CD8
+ T
cell function. Thus, if expression of SLAM on B cells, but not
fibroblasts, controls the effector function of CD8
+ T cells, then it
would be predicted that SAP
2 CD8
+ T cells would exhibit
reduced cytotoxicity against HDLM2 cells than their SAP
+
counterparts. When this was tested experimentally by pulsing
either autologous B-LCLs or MHC class I–matched HDLM2 cells
with CMV peptides and assessing the response of CMV-specific
CD8
+ T cells, both SAP
2 and SAP
+ cells were equally capable of
responding to HDLM2, as evidenced by acquisition of CD107a
expression by a comparable proportion of cells (Figure 7B, lower
panel), but not to B-LCLs, as expected (Figure 7B, upper panel).
This dichotomy in recognising and responding to B-LCLs versus
HDLM2 was not due to differences in expression of MHC class I
by the target APCs (Figure 7A). This finding suggested that SLAM
was unlikely to be the predominant receptor mediating the effector
function of CD8
+ T cells in the absence of SAP.
This led us to focus on NTB-A and 2B4 because their ligands
(i.e., NTB-A, CD48) are highly expressed on B cells (Figure 6;
[22,50]) and they can deliver activating and inhibitory signals in
the presence and absence, respectively, of SAP to human NK and
CD8
+ T cells [22,24,26,27,32]. Although CRACC was also more
highly expressed on human B-LCLs than on monocytes (Figure 6),
its role in regulating CD8
+ T cell function was not explored
because it functions independently of SAP [48,51].
When interactions between NTB-A/NTB-A and/or 2B4/
CD48 were blocked with specific mAbs [22,52–54], activation of
SAP
+ CD8
+ T cells by B cell targets was not significantly affected
(%CD107a
+ cells—no mAb: 51.3%63.8%; + anti-NTB-A mAb:
56%66.5%; + anti-2B4 mAb: 55.7%65.6%; + anti-NTB-A/2B4
mAbs: 55.7%67.3%; n=4, p=0.48 [27,32]). By contrast,
blocking interactions between NTB-A/NTB-A or 2B4/CD48
substantially improved the effector function of SAP
2 CD8
+ T cells
compared to when these cells were examined in the absence of
added mAbs (Figure 7C,D). Importantly, combined blockade of
both pathways could restore effector function of SAP
2 T cells to a
level comparable to SAP
+ clones (Figure 7C). These observations
suggest that signalling through NTB-A and 2B4 impedes the
effector function of SAP-deficient, but not SAP-sufficient, CD8
+ T
cell in response to Ag-presenting B cell targets.
To provide additional data that homotypic NTB-A interactions
can suppress the function of SAP-deficient CD8
+ T cells, we
transfected fibroblasts to express NTB-A (Figure 7E) and
compared the ability of SAP
+ and SAP
2 clones to lyse the
parental (i.e., NTB-A
2) or transduced NTB-A
+ cells in a
51Cr
release assay. Consistent with the data presented in Figure 4, there
was no difference in lysis of either parental fibroblasts by SAP
+ and
SAP
2 CD8
+ T cell clones (compare Figure 7F and G; red lines), or
lysis of NTB-A
2 and NTB-A
+ fibroblasts by SAP
+ CD8
+ T cells
clones (Figure 7F). However, the cytotoxic activity of the same
SAP
2 CD8
+ T cell clone was significantly reduced when NTB-A
was ectopically expressed on fibroblasts (Figure 7G, p,0.05).
Thus, these data provide evidence that in the absence of SAP,
SLAM family receptors acquire inhibitory function which
compromises the ability of CD8
+ T cells to be activated by Ag-
presenting B cells.
Discussion
Primary immune deficiencies are characterised by increased
susceptibility to infection by a range of pathogens [10]. The
molecular mechanism underlying this heightened vulnerability is
often explained by the nature of the genetic defect responsible for a
particular immune deficient condition. Thus, a lack of B cells in X-
linked agammaglobulinemia (XLA) a lack of T and NK cells in X-
linked several-combined immunodeficiency (X-SCID) and im-
paired B-cell responses in X-linked hyper-IgM syndrome due to
mutations in BTK, IL2RG, and CD40LG, respectively, predispose
affected individuals to severe, recurrent, and often life-threatening
infections [10,55]. In contrast to these conditions, the explanation
for why loss-of-function mutations in SH2D1A, resulting in SAP-
deficiency, render XLP patients exquisitely sensitive to infection
with EBV, but not other viruses, is enigmatic. Indeed, while
previous studies that examined lymphocytes from XLP patients or
Sap-deficient mice have clearly shed light on the role of SAP in
different immune cells and allowed us to understand the complex
nature of some of the clinical manifestations of XLP [4,7], the
question of why XLP patients are uniquely susceptible to EBV
infection remains unanswered. Efforts to address this have also
been hampered by the absence of appropriate animal models due
to the specificity of EBV infection for humans. For these reasons,
we developed a novel approach to answer this basic question
relating to XLP.
Female carriers of several X-linked diseases, such as X-SCID,
XLA, and Wiskott-Aldrich syndrome, display skewed X-chromo-
some inactivation with preferential expression of the wild-type
(WT) allele in some lymphocyte lineages [56–58]. This occurs
because expression of the WT allele in specific hematopoietic cells
confers a survival advantage over cells expressing the mutant
allele, which therefore fail to develop in the female carriers. In
contrast to these X-linked diseases, normal numbers of T and NK
cells are detected in XLP patients [11,16], and lymphocytes from
Figure 4. SAP deficient CD8
+ T cells fail to respond to B cell targets. SAP
+ and SAP
2 CD8
+ T cell clones specific for (A, B) CMV or (C–E) Flu
isolated from unrelated XLP carriers were cultured with (A) autologous B-LCLs, (B) B-LCLs or HLA-matched monocytes, or (C–E) B-LCLs or HLA-
matched fibroblasts that had been pulsed with either an irrelevant or cognate peptide for 4–6 h. Stimulation with PMA/Ionomycin was used as a
positive control. Expression of IFN-c (A) or CD107a (B–E) was then determined. The graphs in (D) and (E) represent the percentage of Flu-specific SAP
+
or SAP
2 cells induced to express CD107a
+ following stimulation with peptide-pulsed B-LCLs (D) or fibroblasts (E). The values represent the mean 6
sem of experiments using three different Flu-specific SAP
+ or SAP
2 clones. (F, G) SAP
+ and SAP
2 Flu-specific CD8
+ T cell clones were cultured with
51Cr-labelled B-LCLs (F) or fibroblasts (G) pulsed with their cognate peptide for 4–6 h. Cytotoxicity was determined by standard chromium-release
assay. The results are representative of two experiments performed using different clonal pairs of SAP
2 and SAP
+ cells. Data presented in Figure S2
for responses to CMV-pulsed B-LCLs and monocytes were obtained from experiments using different pairs of SAP
2 and SAP
+ clones. ** p,0.05.
doi:10.1371/journal.pbio.1001187.g004
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chromosome [11]. These observations demonstrate that SAP is
not required for lymphocyte development (with the exception of
NKT cells [11]; Figures 1, 2). Consequently, female carriers of
XLP represent an ideal model to assess the role of SAP in CD8
+ T
cell-mediated anti-viral immune responses because both SAP
+ and
SAP
2 cells with the same genetic background are generated at
similar frequencies (Figure 2). This is essentially the human
equivalent of a mixed bone marrow chimera in mice, and
therefore eliminates any variability that may arise from compar-
isons of SAP-deficient CD8
+ T cells from XLP patients with SAP-
sufficient cells from unrelated normal donors, as has been
performed in earlier studies [19,20,32]. Another feature of
female XLP carriers is that they have an intact immune system
and are not susceptible to any known infections [38,39]. Thus,
any secondary defects in the function of CD8
+ T cells from XLP
patients due to a lack of NKT cells or impaired NK cell
function—which can all contribute to fine-tuning CD8
+ Tc e l l
responses [33–36]—are circumvented by studying XLP carriers.
These attributes of XLP carriers allowed us to perform a detailed
analysis of the responses of SAP
2 and SAP
+ CD8
+ T cells from
the one individual to not only EBV but other common viruses
including CMV and Flu in the setting of a normal host immune
response.
Figure 5. Expression of SLAM family receptors on CD8
+ T cell subsets in XLP carriers. PBMCs from XLP carriers were stained with mAb
specific for CD8, CD45RA, and CCR7 and either 2B4, NTB-A, CD229, SLAM, CD84, or CRACC; expression of SAP was then detected following fixation
and permeabilisation. Expression of each of the SLAM family members on SAP
2 and SAP
+ naı ¨ve, central memory, effector memory, and TEMRA CD8
+ T
cells was determined by gating on CD45RA
+CCR7
+, CD45RA
2CCR7
+, CD45RA
2CCR7
2, and CD45RA
+CCR7
2 cells, respectively. The histograms in (A)
are derived from analysis of one carrier. Data for all carriers are presented in Figure S3. (B) Representative histogram plots of SLAM family receptor
expression on SAP
+ and SAP
2 CD8
+ T cell clones.
doi:10.1371/journal.pbio.1001187.g005
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specific CD8
+ T cells could be detected in XLP patients (n=2;
[59]). These cells, however, exhibit poor in vitro responses to EBV
Ags [19,32]. Our phenotypic and functional analysis of Ag-specific
CD8
+ T cells from XLP carriers demonstrated that CMV or Flu-
specific CD8
+ T cells are distributed within both SAP
+ and SAP
2
memory populations, however there was a dramatic, and highly
significant, skewing of EBV-specific CD8
+ T cells such that .95%
of these cells were detected within the SAP
+ compartment
(Figure 3). By using peptides derived from both lytic and latent
EBV Ag, we established that the exclusive SAP
+ effector CD8
+ T
cells generated following EBV infection were not restricted to a
single dominant antigenic epitope (Figure 3). This demonstrates
that there is a selective advantage for SAP
+ CD8
+ T cells in anti-
EBV immunity, but not in either anti-CMV or anti-Flu immunity.
Thus, although SAP
2 cells are abundant within the pool of naı ¨ve
CD8
+ T cells, the SAP
+ cells expressing a TCR with specificity for
EBV vigorously outcompete their SAP
2 counterparts and
subsequently become the predominant cell type that expands
and is maintained following exposure to EBV. Thus, our studies
reveal a strong requirement for SAP expression not only in
mediating the effector function of CD8
+ T cells in response to
EBV infection but also in the expansion and survival of these cells.
These findings underscore the obligate requirement for SAP, and
by extension SLAM family receptors, at multiple stages in CD8
+ T
cells in mediating protection against EBV infection. The ability to
examine competition between WT and gene-deficient cells ex vivo
is another powerful feature of the carrier model, and a human
Figure 6. SLAM family receptor ligands are differentially expressed by distinct types of APCs. PBMCs from healthy controls (n=6), B-LCLs
from healthy controls and XLP carriers (n=8), monocyte-derived DCs (n=4), and human fibroblasts (n=2) were stained with mAb specific for SLAM
family receptors CD48, NTB-A, CD229, SLAM, CD84, or CRACC. Monocytes and B cells in the PBMCs were identified by expression of CD14 and CD20,
respectively. DCs were identified by expression of CD1a, CD11c, and MHC class II. (A) Histograms of the expression of ligands of the SLAM family on
human fibroblasts, resting primary B cells, B-LCLs, monocytes, and in vitro–derived DCs. (B) The mean fluorescence intensity of the expression of the
different molecules on different APCs (F, fibroblasts; B, resting primary B cells; L, B-LCLs; M, monocytes; DC, dendritic cells).
doi:10.1371/journal.pbio.1001187.g006
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2 CD8
+ T cells. (A) Expression of SLAM receptors and MHC class I
on B-LCL and the Hodgkin’s lymphoma cell line HDLM2 were determined. (B) The ability of CD8
+ T cells to be activated by B-LCL and HDLM2 cells was
assessed by incubating CMV-specific SAP
2 (red histogram) and SAP
+ (blue histogram) CD8
+ T cells with peptide-pulsed target cells. The values
represent the percentage of CD107a-expressing SAP
2 and SAP
+ cells detected after 4–6 h incubation with the different target cells. (C, D) SAP
+ and
SAP
2 CD8
+ T cell clones specific for CMV were cultured with peptide-pulsed autologous B-LCLs in the presence or absence of specific mAb to NTBA
alone, 2B4 alone, or in combination. Expression of CD107a by SAP
2 and SAP
+ CD8
+ T cells was determined after 4–6 h. The values represent the
proportion of responding cells. The data presented in (C) and (D) represent independent experiments performed using different pairs of CMV-specific
CD8
+ T cell clones. (E) Expression of NTB-A on parental fibroblasts (red histogram) or those transfected to express NTB-A (blue histogram). (F, G) SAP
+
(F) and SAP
2 (G) CMV-specific CD8
+ T cells clones were cultured with
51Cr-labelled parental (red) or NTB-A-expressing (blue) fibroblast target cells.
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marrow chimeras to determine the intrinsic responses of WT
versus mutant cells in a competitive environment.
The mechanism underlying this fundamental requirement for
SAP expression during the generation of EBV-specific CD8
+ T
cells was revealed by investigating the ability of SAP
2 and SAP
+
CD8
+ T cells specific for the same CMV or Flu epitopes to
respond to their cognate peptide when presented on B-cell or non-
B-cell target APCs (monocytes, DCs, fibroblasts). The rationale for
these experiments was 2-fold: first, one of the key differences
between the three viruses studied here is the identity of the APC
responsible for activating the CD8
+ T cell response. CMV persists
in immature myeloid cells and, on reactivation, is likely to be
presented by infected monocytes/DCs [60], whereas influenza
infects respiratory epithelial cells and can be cross-presented by
DCs [61]. By contrast, EBV is a predominantly B-lymphotrophic
virus and there is strong evidence to suggest that the CD8
+ T cell
response is driven by epitopes displayed on infected B cells
themselves [37,62]. Second, although the response of XLP CD8
+
T cells to B cells is impaired, they can respond relatively normally
to other types of target cells [19,32]. Thus, it was possible that
SAP-deficient CD8
+ T cells failed to be activated when Ag was
specifically presented by B cells. Indeed, SAP-deficient CD8
+ T
cell clones from XLP carriers were specifically defective in
responding to their cognate epitopes when presented by B-cell,
but not non-B-cell, targets irrespective of the viral origin of the
specific Ag (Figure 4). Similarly, EBV-specific SAP-deficient CD8
+
T cells expanded from XLP patients were severely compromised
in their capacity to lyse B cells presenting endogenously processed
EBV peptide Ags (Figure S2C). Our findings have several
important implications. First, although EBV can presumably be
presented by numerous non-B-cell types of APCs (e.g., tonsillar
epitheilium, cross-primed DCs) [63,64], and this may contribute to
the initial generation of detectable EBV-specific CD8
+ T cells in
XLP patients [19,59], the predominant APC involved in
maintaining a robust anti-EBV CD8
+ T cell–mediated immune
response appears to be B cells. Second, the inability to control
EBV infection in XLP is likely to result from a direct defect in
CD8
+ T cells. Defects in CD4
+ T cells may contribute to impaired
anti-EBV immunity in XLP because analysis of the CD4
+ T cell
compartment from XLP carriers revealed a predominant response
by SAP
+ CD4
+ T cells to EBV lysate in vitro (Figure S4). Third,
and most importantly, the exquisite sensitivity of XLP patients to
EBV infection results from the ability of the virus to sequester itself
in infected B cells which can only induce a cytotoxic T cell
response in SAP-sufficient cells. In other words, the functional
defect in SAP
2 CD8
+ T cells does not relate to a specific virus but
rather to the nature of the target cell presenting viral epitopes.
The finding of a requirement for SAP in CD8
+ T cell–mediated
lysis of Ag-presenting B cells, but not monocytes, DCs, or
fibroblasts, predicted that expression of ligands of the SLAM
family would differ between these populations of APCs. This was
confirmed by demonstrating that while fibroblasts lacked expres-
sion of all SLAM family ligands, B cells, monocytes, and DCs
expressed differing levels of some of these ligands (Figure 6).
Signalling downstream of SLAM family receptors is regulated by
SAP via several mechanisms. SAP can deliver activation signals via
Fyn-dependent or Fyn-independent processes [6]. Alternatively,
SLAM family receptors can alter their function to become
inhibitory receptors in the absence of SAP [5,6]. This appears to
be mediated by the recruitment and/or activation of inhibitory
phosphatases [22,24,65,66]. We therefore reasoned that engage-
ment of SLAM receptors delivered either activating signals to
SAP-expressing CD8
+ T cells or inhibitory signals to SAP-deficient
CD8
+ T cells. Our finding that (1) impeding NTB-A/NTB-A and
2B4/CD48 interactions with blocking mAbs [22,52,54] could
improve the function of SAP
2 CD8
+ T cells in the context of
responses to Ag-presenting B cell targets and (2) ectopic expression
of NTB-A on fibroblasts protected these cells from cytotoxicity
induced by SAP-deficient Ag-specific CD8
+ T cells favoured an
inhibitory function for these receptors in the absence of SAP
(Figure 7). This is reminiscent of early descriptions of inhibitory
function of these receptors on SAP-deficient human NK cells
[22,24,67,68], and the recent demonstration of such a phenom-
enon for CD8
+ T cell clones from XLP patients [32]. This
conclusion is also consistent with the reported ability of NTB-A to
associate with SHP-1 in the absence of SAP in human NK cells
and T cells [22,42], thereby suggesting a mechanism of how NTB-
A exerts its inhibitory effect. Veillette and colleagues proposed that
the SAP homolog EAT-2 mediates inhibitory signalling down-
stream of some SLAM family receptors in the absence of SAP
[69]. Interestingly, EAT-2 associates with NTB-A in human
lymphocytes [70], and SH2D1B (encoding EAT-2) was expressed
at increased levels in memory CD8
+ T cells from XLP patients
compared to healthy donors (Figure S5). Thus, it is possible that in
XLP heightened expression of EAT-2 mediates an alternative
pathway downstream of NTB-A for inhibitory signalling in SAP-
deficient CD8
+ T cells following engagement of SLAM family
receptors. Irrespective of these possibilities, it is clear that
expression of SAP significantly alters the function of SLAM family
receptors on human NK and CD8
+ T cells such that these
receptors inhibit cytotoxicity in the absence of SAP.
Previous studies established defects in SAP-deficient CD8
+ T
cells [19,20,32]. However, there have been major limitations to all
of these inasmuch as they only examined responses of XLP CD8
+
T cells to polyclonal (i.e., Ag non-specific) stimulation [19,20], or
only studied responses to EBV and not additional viruses [19,32].
Thus, none of these earlier studies offered an explanation for the
selective inability of XLP patients to respond to infection with
EBV but not other viruses. We have now significantly extended
these observations by providing mechanistic insight into the
dysfunctional behaviour of SAP
2 CD8
+ T cells by (1) revealing
that the defect in anti-EBV immunity in XLP reflects the nature of
the APC, rather than EBV itself, (2) proving that NTB-A is
inhibitory for the function of SAP-deficient CD8
+ T cells, and (3)
excluding a role for SLAM itself in regulating the function of
human Ag-specific CD8
+ T cells, a scenario proposed by a
previous study [49].
Our findings that SAP-deficient CD8
+ T cells respond poorly to
EBV-infected B cells, but not to monocyte, DC, or fibroblast
APCs, parallel those reported recently for CD4
+ T cells from
Sap
2/2 mice. In that system no difference was found in the quality
of interactions between DCs and either SAP-deficient or SAP-
sufficient CD4
+ T cells [17]. However, SAP-deficient CD4
+ T cells
exhibited greatly reduced interactions with cognate B cells,
resulting in impaired help for T-dependent B cell responses [17].
Interestingly, mouse Ly108 (i.e., human NTB-A) is involved in the
formation of stable conjugates between normal CD4
+ T cells and
B cells, while interactions with DCs were predominantly mediated
by integrins [71]. The absence of NTB-A and CD48 from DCs
Cytotoxicity was determined after 4 h and is expressed as percentage of Target cell lysis. Each value is the mean 6 sem of triplicate samples and is
representative of experiments performed using three different pairs of SAP
2 and SAP
+ CMV-specific CD8
+ T cell clones.
doi:10.1371/journal.pbio.1001187.g007
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+ T
cells is unaffected by SAP deficiency. While SAP was required in
murine CD4
+ T cells for NTB-A-mediated interactions with B
cells [71], it appears that SAP functions in human CD8
+ T cells to
prevent the delivery of inhibitory signals downstream of NTB-A
that probably involve the recruitment and/or activation of
phosphatases or EAT-2 [22,42,70]. This apparent disparate
function of NTB-A on murine CD4
+ and human CD8
+ T cells
may be explained by the pattern of expression of EAT-2,
inasmuch as it is detected in human CD8
+ T cells (Figure S5)
[72], but not murine CD4
+ T cells [69]. Despite these potential
differences, an emerging theme is that loss of SAP in T cells leads
to altered interactions with B cells, while interactions with other
APCs remain intact. This specific defect not only explains the
molecular pathogenesis of the unique susceptibility to EBV
infection in XLP patients but potentially explains their high
incidence of B-lymphomas. Interestingly, EBV is the only known
human pathogen that selectively infects B cells, which results in
expression of high levels of SLAM family ligands to facilitate the
T-B cell cross-talk necessary for immunity. Thus, our studies have
identified a unique pathological signalling pathway that may be
targeted to treat patients with severe EBV infection. Furthermore,
the innovative XLP carrier model has allowed us to unravel the
mechanisms of disease in the absence of a relevant animal model.
This system may also allow the study of other human diseases, for
instance XIAP deficiency, which also predisposes to EBV infection
[8,73], where heterozygous gene expression from random X-
chromosome inactivation could be exploited.
Materials and Methods
XLP Carriers and Patients
Blood samples were collected from seven different XLP carriers
and an XLP patient. PBMC were isolated and either used fresh or
cryopreserved in liquid nitrogen. Genomic DNA was sequenced to
confirm the heterozygous state of the carriers. Primers used for
amplification of the four exons of SH2D1A are: Exon 1 sense: CAA
CAT CCT GTT GTT GGG G, Exon 1 antisense: CCA GGG
AAT GAA ATC CCC; Exon 2 sense: GCA ATG ACA CCA
TAT ACG, Exon 2 antisense: GAA CAA TTT TGG ATT GGA
GC; Exon 3 sense: GTA AGC TCT TCT GGA ATG, Exon 3
antisense: CAT CTA CTT TCT CAC TGC; Exon 4 sense: CTG
TGT TGT GTC ATT GTG, Exon 4 antisense: GCT TCC ATT
ACA GGA CTA C. All participants gave written informed
consent and the experiments were approved by the Human
Research Ethic committees of the Sydney South West Area Health
Service (Royal Prince Alfred and Concord Zones) and St.
Vincent’s Hospital.
Flow Cytometric Analysis
PBMC, CD8 T cell clones, B-LCLs, and fibroblasts were
stained with fluorochrome-conjugated mAbs specific for cell
surface receptors. The following mAbs were used to identify
different lymphocyte populations: anti-CD3, CD4, CD8 (T cells),
CD56 (NK cells), CD20 (B cells), CD14 (monocytes), CD1a,
CD11c (DC) (BD Biosciences), and TCR Va24/Vb11 (NKT cells)
(Immunotech, France) mAbs. CCR7 (R&D Systems), CD45RA
(BD Biosciences), and CD27 (BD Biosciences) were used to
identify subsets of naı ¨ve and memory T and B cells. CD83
(eBioscience), CD86, MHC class II, and MHC class I mAbs (BD
Biosciences) were used to phenotype LPS-matured DCs. Expres-
sion of the SLAM family of receptors and ligands was determined
using mAbs against CD84 (BD Biosciences), CD229, NTBA,
CRACC (R&D Systems), 2B4 (Beckman Coulter), CD48 (Im-
munotech, France), and SLAM/CD150 (eBiosciences). TCR Vb
repertoire analysis was performed according to the manufacturer’s
instructions (Beckman Coulter). For degranulation assays mAb
against CD107a (BD Biosciences) was used as previously described
[44,45] and for intracellular cytokine stains anti-IFN-c (BD
Biosciences) mAb was used. Stained cells were analyzed on either
FACSCanto I or II flow cytometers (BD Biosciences) and the data
processed using FlowJo software (Treestar, Ashland, USA).
MHC Class I Tetramers
MHC class I tetramers were prepared in-house, where the
appropriate MHC class I heavy chain molecule was refolded with
b2 microglobulin and the peptide and complexed with streptavi-
din-PE as described [74]. CMV epitopes used were the HLA-
A*0201-restricted peptides NLVPMVATV from pp65 (UL83)
protein, and VLEETSVML from IE-1 (UL122) protein; HLA-
A*0101 restricted peptide, VTEHDTLLY from pp50 (UL44)
protein. EBV epitopes used were HLA-A*0201-restricted GLCT-
LVAML from the lytic Ag BMLF-1, CLGGLLTMV from LMP2,
HLA-B*4402-restricted peptides VEITPYKPTW from EBNA3B
latent protein, and EENLLDFVRF from EBNA3C. The influenza
A epitope was the HLA-A*0201-restricted peptide GILGFVFTL
from matrix protein.
Detection of SAP by Intracellular Staining
Cells were first stained for surface markers and then fixed with
2% paraformaldehyde, permeabilized with 0.5% saponin, and
incubated with Alexa Fluor 647 (Invitrogen)-conjugated isotype
control or anti-SAP mAb (Abnova, clone 1C9). Cells were washed
and resuspended in PBS/1% FCS and analysed on a FACSCanto
I or II flow cytometer (BD Biosciences).
PBMC Stimulation
1–2610
6 PBMCs were stimulated with either an irrelevant
peptide, specific MHC class I restricted synthetic peptide, or
PMA/ionomycin as a positive control for 4–6 h in the presence of
Brefeldin A (for IFN-c production) or monensin (for CD107a
expression). The capacity to respond to these peptides was tested
by harvesting the cells and determining expression of IFN-c or
CD107a by SAP
+ and SAP
2 CD8
+ T cells.
Generation and Culture of Human Monocyte-Derived
Dendritic Cells
DCs were generated from peripheral blood monocytes by
culturing sort-purified CD14
+ cells (5610
5/ml) in human
lymphocyte media [15,16] supplemented with 500 U/ml of IL-4
(provided by Dr. Rene de Waal Malefyt) and 50 ng/ml GMCSF
(Peprotech). After 5 d, monocyte-derived DCs were harvested,
washed, and cultured (5610
5/ml) in the presence of 1 mg/ml of
LPS (Sigma) for a further 18 h. Monocyte-derived DCs were
CD1a
+ CD11c
+ CD14
2. Upon maturation with LPS, they
upregulated expression of CD83, CD86, and MHC class I and
MHC class II.
Generation of Ag-Specific T Cell Clones and Lines
Virus-specific CD8
+ T cell clones were established from PBMCs
by sort-purifying tetramer positive cells and limiting dilution
cloning as described [75]. Clones were established by seeding sort-
purified tetramer
+ CD8
+ T cells at 0.3–3 cells/well into media
containing 10
4 autologous B-LCLs and 10
5 feeder cells per well.
CMV-specific clones were selected based on their recognition of
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while influenza-specific clones recognised the matrix protein
epitope GILGFVFTL (HLA-A2 restricted). All clones were
expanded and tested for specificity by staining with the
appropriate tetramer and for SAP expression (see Figure S1).
EBV-specific CD8
+ T cell lines used in DC assays were generated
by sort purifying tetramer-positive cells and expanding them in
vitro on peptide-pulsed autologous B-LCLs and feeder cells. EBV-
specific CD8
+ T cell lines from XLP patients and normal donors
were established by repeated stimulation of purified CD8
+ T cells
on autologous B-LCLs [19].
T Cell Recognition Assay
The ability of CD8
+ T cell clones to respond to various target
cells was measured either by intracellular IFN-c staining or by
staining for CD107a. Autologous B-LCLs were used as B cell
targets. HLA-matched monocytes were sort-purified from buffy
coats on the basis of CD14 (Immunotech) expression and used as
APCs. DCs were generated as described above. HLA-matched
human fibroblasts used were JuSt (HLA-A1 & A2) and MeWo cells
(HLA A2) (ATCC). All APCs were pulsed with appropriate
peptides (1 mg/ml) and used to stimulate CD8
+ T cell clones.
Where cytotoxicity was measured, APCs were sensitised with
cognate peptide at a concentration of 1 mg/ml while loading with
51Cr. After washing, T cells were incubated at different APC:T cell
ratios and incubated for 5 h in standard cytotoxicity assay [75]. In
some experiments, blocking mAbs against NTB-A (MA127) [22]
and 2B4 (C1.7 [52,53]) were used to prevent NTB-A/NTB-A and
2B4/CD48 interactions, respectively. B-LCLs were incubated with
the relevant mAb at a final concentration of 20 mg/ml for 30–
45 min prior to mixing with CTL clones. Cultures were incubated
for 4–6 h in the presence of blocking mAbs and mAb to CD107a.
Cells were then appropriately stained and analysed by flow
cytometry. Fibroblasts were transfected using Lipofectamine with
the pcdef3 plasmid containing cDNA encoding human NTB-A.
Positive cells were initially selected in the presence of G418 and
then isolated by sorting NTB-A
+ cells. NTB-A
+ transfected and
untransfected parental fibroblasts were then used as targets in
51Cr
release assay as described above.
Supporting Information
Figure S1 Generation of SAP
2 and SAP
+ virus-specific clones.
Virus-specific cells were isolated from PBMCs of XLP carriers by
sorting tetramer
+ cells (A). Clones were then established by
limiting dilution assay and positive clones were expanded. All
clones were then examined for their expression of SAP by
intracellular staining (B) and specificity by tetramer staining (C).
(TIF)
Figure S2 SAP deficient CD8
+ T cells fail to respond to B cell
targets. (A) Ag-specific SAP
+ (upper panel) and SAP
2 (lower panel)
CD8
+ T cell clones or (B) EBV-specific CD8
+ T cell lines isolated
from an XLP carrier were cultured with (A) autologous B-LCLs or
HLA-matched monocytes or (B) autologous B-LCLs or HLA-
matched DCs that had been pulsed with either an irrelevant or
cognate peptide for 4–6 h. Stimulation with PMA/Ionomycin was
used as a positive control. Expression of CD107a was then
determined. These results are derived from different sets of clones
as those presented in Figure 4. (C) EBV-specific CD8
+ T cell lines
were established from a healthy control or an XLP patient. The
ability of these cells to lyse autologous (panel [i]) and allogeneic but
HLA-matched (panel [ii]) B-LCLs was measured using a standard
4-h
51Cr release assay. Expression of perforin and granzyme B in
CD8
+ T cell lines from the healthy control and XLP patient was
also determined (panel [iii]).
(TIF)
Figure S3 Expression of SLAM family receptors on CD8
+ T cell
subsets in XLP carriers. PBMCs from four different XLP carriers
were stained with mAb specific for CD8, CD45RA, and CCR7
and either 2B4, NTB-A, CD229, SLAM, CD84, or CRACC;
expression of SAP was then detected following fixation and
permeabilisation. Expression of each SLAM family member on
SAP
2 and SAP
+ naı ¨ve, central memory, effector memory,
and TEMRA CD8
+ T cells was determined by gating on
CD45RA
+CCR7
+, CD45RA
2CCR7
+, CD45RA
2CCR7
2, and
CD45RA
+CCR7
2 cells, respectively. The graphs show data points
(mean fluorescence intensity) for all carriers examined (n=4); the
horizontal bar represents the mean.
(TIF)
Figure S4 EBV-specific CD4 T cells are largely SAP
+. PBMCs
from two XLP carriers were either unstimulated or stimulated with
EBV lysate or anti-CD3/anti-CD28 mAbs. Expression of IFN-c
by SAP
+ and SAP
2 CD4
+ T cells was determined after 4–6 h. The
values represent the proportion of responding cells that were
SAP
2 or SAP
+.
(TIF)
Figure S5 Increased expression of SH2D1B in SAP-deficient
XLP memory CD8
+ T cells. CD8
+ T cell subsets corresponding to
naı ¨ve, central memory, effector memory, and TEMRA CD8
+ T
cells were isolated from the peripheral blood of two healthy
controls and two XLP patients. Expression of SH2D1B, encoding
the SAP-related homolog EAT-2, was determined by microarray
analysis using Human Genome U133 Plus 2.0 Affymetrix Arrays
and GeneSpring software.
(TIF)
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